Human disorders of ubiquitination and proteasomal degradation

Current Opinion in Pediatrics

Volumn 16, Issue 4, 2004, Pages 419-426

  Jiang, Yong Hui ^a   Beaudet, Arthur L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Deubiquitinases; Inborn errors; Ligases; Proteasome; Ubiquitin

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGASE; POLYGLUTAMINE; PROTEASOME; UBIQUITIN;

ALZHEIMER DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOSOMAL RECESSIVE DISORDER; CELL FUNCTION; CYLINDROMA; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; EXPERIMENTAL MOUSE; FANCONI ANEMIA; GENE LOCUS; GENETIC DISORDER; GERM LINE; HAPPY PUPPET SYNDROME; HUMAN; INCONTINENTIA PIGMENTI; LIDDLE SYNDROME; METABOLIC DISORDER; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; VON HIPPEL LINDAU DISEASE;

ALZHEIMER DISEASE; ANGELMAN SYNDROME; ANIMALS; FANCONI ANEMIA; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HIPPEL-LINDAU DISEASE; HUMANS; NF-KAPPA B; POLYENDOCRINOPATHIES, AUTOIMMUNE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 3442900482     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000133634.79661.cd     Document Type: Review

References (80)

1. Pickart CM: Back to the future with ubiquitin. Cell 2004, 116:181-190. Single most valuable recent reference on ubiquitin.
2. Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899. Excellent review of relation to misfolded proteins.
3. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70:503-533.
4. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
5. Weissman AM: Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001, 2:169-178.
6. Baumeister W, Walz J, Zuhl F, et al.: The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998, 92:367-380.
7. Maniatis T: A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 1999, 13:505-510.
8. Lee JC, Peter ME: Regulation of apoptosis by ubiquitination. Immunol Rev 2003, 193:39-47.
9. Wang T: The 26S proteasome system in the signaling pathways of TGF-beta superfamily. Front Biosci 2003, 8:d1109-d1127.
10. Cremona O, Collesi C, Raiteri E: Protein ubiquitylation and synaptic function. Ann N Y Acad Sci 2003, 998:33-40.
11. Rome S, Meugnier E, Vidal H: The ubiquitin-proteasome pathway is a new partner for the control of insulin signaling. Curr Opin Clin Nutr Metab Care 2004, 7:249-254.
12. Schwartz DC, Hochstrasser M: A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci 2003, 28:321-328. Discusses SUMO and SUMOylation, which are not covered in this review.
13. Lieberman AP: SUMO, a ubiquitin-like modifier implicated in neurodegeneration. Exp Neurol 2004, 185:204-207.
14. Uchida D, Hatakeyama S, Matsushima A: AIRE functions as an E3 ubiquitin ligase. J Exp Med 2004, 199:167-172. Latest information on APECED
15. Meetei AR, de Winter JP, Medhurst AL: A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003, 35:165-170. Essentials of Fanconi anemia and ubiquitination.
16. Koegl M, Hoppe T, Schlenker S: A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999, 96:635-644.
17. Hatakeyama S, Nakayama KI: U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 2003, 302:635-645.
18. Matsumoto M, Yada M, Hatakeyama S: Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J 2004, 23:659-669.
19. Papa FR, Hochstrasser M: The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene. Nature 1993, 366:313-319.
20. Fischer JA: Deubiquitinating enzymes: their roles in development, differentiation, and disease. Int Rev Cytol 2003, 229:43-72. Recent review of deubiquitinases.
21. Cip1 ubiquitination. Mol Cell 2000, 5:403-410.
22. Kishino T, Lalande M, Wagstaff J: UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997, 15:70-73.
23. Matsuura T, Sutcliffe JS, Fang P: De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997, 15:74-77.
24. Yamasaki K, Joh K, Ohta T: Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum Mol Genet 2003, 12:837-847. Recent evidence for genomic imprinting in neurons but not glia.
25. Jiang Y-H, Lev-Lehman E, Bressler J: Genetics of Angelman syndrome. Am J Hum Genet 1999, 65:1-6.
26. Jiang Y, Bressler J, Beaudet AL: Epigenetics and human disease. Annu Rev Genomics Hum Genet 2004, (In press) Recent and in-depth review of the role of epigenetics in human diseases.
27. Jiang Y, Armstrong D, Albrecht U: Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998, 21:799-811.
28. Weeber EJ, Jiang YH, Elgersma Y: Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neurosci 2003, 23:2634-2644. Recent effort to understand the function of ubiquitination in Angelman syndrome.
29. Upadhya SC, Hegde AN: A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins. Trends Biochem Sci 2003, 28:280-283.
30. Staropoli JF, McDermott C, Martinat C: Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003, 37:735-749. Up-to-date perspective on mutations in parkin causing Parkinson disease.
31. Dev KK, van der Putten H, Sommer B, et al.: Part I: parkin-associated proteins and Parkinson's disease. Neuropharmacology 2003, 45:1-13.
32. Goldberg MS, Fleming SM, Palacino JJ: Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003, 278:43628-43635.
33. Lockhart PJ, O'Farrell CA, Farrer MJ: It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG). Mov Disord 2004, 19:101-104.
34. Lorenzetti D, Antalffy B, Vogel H: The neurological mutant quaking (viable) is Parkin deficient. Mamm Genome 2004, 15:210-217.
35. Lisztwan J, Imbert G, Wirbelauer C: The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999, 13:1822-1833.
36. Lonser RR, Glenn GM, Walther M: von Nippel-Lindau disease. Lancet 2003, 361:2059-2067.
37. Kamura T, Brower CS, Conaway RC, et al.: A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 2002, 277:30388-30393.
38. Ang SO, Chen H, Hirota K: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002, 32:614-621.
39. Pastore YD, Jelinek J, Ang S: Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003, 101:1591-1595.
40. Pastore Y, Jedlickova K, Guan Y: Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003, 73:412-419. Most up-to-date review on von Hippel-Lindau syndrome and polycythemia due to mutations in VHL.
41. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al.: Congenital disorder of oxygen-sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004, 103:3924-3932.
42. Garcia-Higuera I, Taniguchi T, Ganesan S: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262.
43. Meetei AR, Yan Z, Wang W: FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 2004, 3:179-181. Recent and novel information on Fanconi and BRCA1/BRCA2 signaling.
44. Pichierri P, Rosselli F: The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J 2004, 23:1178-1187. Recent and novel information on Fanconi and BRCA1/BRCA2 signaling.
45. Hussain S, Wilson JB: Medhurst AL, et al.: Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 2004, 12:2503-2510. Recent and novel information on Fanconi and BRCA1/BRCA2 signaling.
46. O'Driscoll M, Ruiz-Perez VL, Woods CG, et al.: A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003, 33:497-501. Relations of Fanconi signaling to ataxia-telangiectasia and Seckel syndrome.
47. Dixit V, Mak TW: NF-κB signaling. Many roads lead to Madrid. Cell 2002, 111:615-619.
48. Smahi A, Courtois G: Vabres P, et al.: Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000, 405:466-472.
49. Doffinger R, Smahi A, Bessia C, et al.: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat Genet 2001, 27:277-285.
50. Jain A, Ma CA, Liu S, et al.: Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001, 2:223-228.
51. Smahi A, Courtois G, Rabia SH, et al.: The NF-κκB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002, 11:2371-2375.
52. Biggs PJ, Wooster R, Ford D, et al.: Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet 1995, 11:441-443.
53. Bignell GR, Warren W, Seal S, et al.: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000, 25:160-165.
54. Lakhani SR: Putting the brakes on cylindromatosis? N Engl J Med 2004, 350:187-188.
55. Brummelkamp TR, Nijman SM, Dirac AM, et al.: Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003, 424:797-801. Relation of cylindromatosis to NF-κB signaling.
56. Kovalenko A, Chable-Bessia C, Cantarella G, et al.: The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 2003, 424:801-805. Relation of cylindromatosis to NF-κB signaling.
57. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al.: CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 2003, 424:793-796.
58. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003, 29(Suppl 1):33-39. Relation of cylindromatosis to NF-κB signaling.
59. Wilkinson KD: Signal transduction: aspirin, ubiquitin and cancer. Nature 2003, 424:738-739.
60. Hu G, Onder M, Gill M: A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome. J Invest Dermatol 2003, 121:732-734. Other phenotypes related to cylindromatosis.
61. Zheng G, Hu L, Huang W: CYLD mutation causes multiple familial trichoepithelioma in three Chinese families. Hum Mutat 2004, 23:400. Other phenotypes related to cylindromatosis.
62. Zhang XJ, Liang YH, He PP: Identification of the cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma. J Invest Dermatol 2004, 122:658-664. Other phenotypes related to cylindromatosis.
63. Michalik A, Van Broeckhoven C: Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 2003, 12:R173-R186. Recent overview of ubiquitination and proteasomal degradation.
64. Tarlac V, Storey E: Role of proteolysis in polyglutamine disorders. J Neurosci Res 2003, 74:406-416.
65. Bence NF, Sampat RM, Kopito RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
66. Ciechanover A, Brundin P: The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446. Excellent recent and in-depth overview of ubiquitination and proteasomal degradation.
67. Lindsten K, Menendez-Benito V, Masucci MG, et al.: A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol 2003, 21:897-902. A novel transgenic mouse model with a signal for ubiquitination fused to GFP.
68. Hernandez F, Diaz-Hernandez M, Avila J, et al.: Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. Trends Neurosci 2004, 27:66-69. A novel transgenic mouse model with a signal for ubiquitination fused to a reporter protein.
69. Lam YA, Pickart CM, Alban A, et al.: Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci U S A 2000, 97:9902-9906.
70. Ding Q, Keller JN: Does proteasome inhibition play a role in mediating neuropathology and neuron death in Alzheimer's disease? J Alzheimers Dis 2003, 5:241-245. Relevance of ubiquitination and proteasomal degradation to Alzheimer disease.
71. van Leeuwen FW, de Kleijn DP, van den Hurk HH: Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998, 279:242-247.
72. De Vrij FM, Sluijs JA, Gregori L: Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death. FASEB J 2001, 15:2680-2688.
73. Fischer DF, De Vos RA, Van Dijk R: Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 2003, 17:2014-2024. More on an unusual form of transcriptional misreading leading to a mutant isoform of ubiquitin in normal individuals in the absence of a DNA mutation; relevance to Alzheimer disease.
74. van Leeuwen FW, Hol EM, Hermanussen RW: Molecular misreading in non-neuronal cells. FASEB J 2000, 14:1595-1602.
75. Warnock DG: Liddle syndrome: genetics and mechanisms of Na+ channel defects. Am J Med Sci 2001, 322:302-307.
76. Staub O, Gautschi I, Ishikawa T: Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J 1997, 16:6325-6336.
77. Abriel H, Loffing J, Rebhun JF: Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. J Clin Invest 1999, 103:667-673.
78. a18H mice. Nat Genet 1998, 18:143-146.
79. Gelman MS, Kopito RR: Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. Methods Mol Biol 2003, 232:27-37. Relevance of ubiquitination and proteasomal degradation to the pathogenesis of cystic fibrosis.
80. Sharma M, Pampinella F, Nemes C: Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 2004, 164:923-933. Relevance of ubiquitination and proteasomal degradation to the pathogenesis of cystic fibrosis.